Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence

Patrick Aouad, Yueyun Zhang, Fabio De Martino, Céline Stibolt, Simak Ali, Giovanna Ambrosini, Sendurai A. Mani, Kelly Maggs, Hazel M. Quinn, George Sflomos, Cathrin BriskenNature Communications 2022 · DOI

TL;DR

Estrogen receptor-positive (ER+) breast cancer cells can lie dormant for years after treatment, leading to late recurrences. This study reveals that epithelial-mesenchymal plasticity (EMP) is key to ER+ cancer cell dormancy, and restoring epithelial characteristics can reawaken these dormant cells, offering a potential therapeutic target.

What Problem Does This Paper Address?

A significant clinical challenge in treating ER+ breast cancer is its tendency to recur decades after initial therapy. The mechanisms behind this "dormancy" and late recurrence are poorly understood, partly due to a lack of suitable animal models that accurately mimic human disease progression. Existing models often fail to capture the specific behaviors of ER+ disseminated tumor cells (DTCs) in a clinically relevant manner. This paper aims to address this gap by developing and utilizing a novel intraductal xenograft model to investigate ER+ breast cancer dormancy and its underlying mechanisms.

Methods

The researchers employed a sophisticated intraductal xenograft model in immunocompromised mice (MIND models). This approach involves injecting human breast cancer cell lines or patient-derived xenografts (PDXs) directly into the milk ducts of the mammary gland, which better mimics the natural progression of breast cancer compared to subcutaneous injections.

Key techniques and analyses included:

  • Bioluminescence imaging: Used to track tumor growth and dissemination of cancer cells in vivo.
  • Fluorescence stereomicroscopy and immunohistochemistry (IHC): To visualize and characterize disseminated tumor cells (DTCs) in various organs and assess their morphology and protein expression.
  • Cell cycle analysis (FUCCI reporter): To determine the proliferative status of DTCs.
  • Gene expression analysis (RT-PCR, microdissection): To quantify the expression of genes associated with epithelial-mesenchymal plasticity (EMP), dormancy, and proliferation.
  • RNA velocity analysis: A cutting-edge technique to infer the dynamic changes in gene expression and predict cell state transitions.
  • Genetic manipulation: Downregulation of E-cadherin (CDH1) and overexpression of EMP-related transcription factors (like ZEB1) to induce EMP, and overexpression of E-cadherin to revert cells to an epithelial state.
  • Single-cell RNA sequencing (scRNA-seq): To comprehensively analyze the heterogeneity of primary tumor cells and DTCs and identify distinct cell populations.

Datasets

The study utilized several human breast cancer cell lines (MCF-7, T47D, BT20, HCC1806) and patient-derived xenografts (PDXs) representing both ER+ and triple-negative (TN) subtypes. These were used to establish the intraductal xenograft models.

The scRNA-seq data generated from primary tumor cells and lung DTCs of MCF-7 xenografts was deposited in the Gene Expression Omnibus (GEO) database under accession code GSE196936.

Key Insights and Ideas

  • EMP is the hallmark of ER+ dormancy: Unlike triple-negative breast cancer (TNBC) DTCs, which remain proliferative, ER+ DTCs enter a dormant state characterized by epithelial-mesenchymal plasticity (EMP). This involves a shift towards a more mesenchymal phenotype, with decreased E-cadherin and increased expression of EMT transcription factors like ZEB1.
  • Dormancy is a reversible state: The study demonstrates that forcing ER+ DTCs to reacquire epithelial characteristics, specifically by restoring E-cadherin expression, can overcome dormancy and reinitiate proliferation. This suggests that the mesenchymal state is crucial for maintaining dormancy.
  • Microenvironment plays a role in awakening: Cytokine signaling, particularly IL-6-induced STAT3 activation, appears to be a key trigger for awakening dormant DTCs. This signaling can directly influence the expression of genes like E-cadherin, promoting a transition back to an epithelial state.
  • Intraductal xenografts are powerful models: The MIND model effectively recapitulates key aspects of ER+ breast cancer progression, including dormancy and late recurrence, making it a valuable tool for studying these phenomena.
  • ESR1 mutations alone are not sufficient for awakening: While ESR1 mutations are common in recurrent ER+ breast cancer, they did not, in this model, directly cause dormant DTCs to reawaken. This suggests other mechanisms are at play.

Key Results

  • ER+ DTCs in the lungs exhibited significantly reduced proliferation (lower Ki67 index) and a higher proportion of cells in the G0/G1 phase compared to primary tumors.
  • ER+ DTCs showed a mesenchymal morphology and increased expression of EMP markers (ZEB1, ZEB2, VIM) and decreased expression of epithelial markers (CDH1).
  • Forced expression of E-cadherin in ER+ DTCs (MCF-7 cells) led to reacquisition of an epithelial state, increased proliferation, and a significant increase in lung micro-metastasis.
  • Genetic manipulation to induce EMP (CDH1 knockdown or ZEB1 overexpression) in ER+ cells did not increase primary tumor growth or metastatic propensity, suggesting that EMP is primarily a mechanism for dormancy rather than invasion in this context.
  • Single-cell RNA sequencing revealed distinct populations of DTCs, with "inactive" clusters showing EMT signatures and "active" clusters exhibiting proliferative and epithelial markers.

Limitations and Future Work

  • Immune system absence: The MIND models utilize immunocompromised mice, which limits the study of how the immune system might influence DTC dormancy and awakening. Future work could involve restoring a functional human immune system.
  • In vitro vs. in vivo plasticity: RNA velocity analysis, while powerful, primarily predicts short-term cell state transitions. Further studies are needed to fully understand the long-term in vivo plasticity of DTCs.
  • Barcoding experiments: To definitively distinguish between primary tumor cells and DTCs that may have undergone EMP, barcoding experiments are suggested.
  • Therapeutic targeting: The findings suggest that targeting the exit from EMP or the signaling pathways that promote awakening (like IL-6/STAT3) could be promising therapeutic strategies for preventing late recurrence in ER+ breast cancer. The study also hints that CDK4 inhibitors might play a role by blocking exit from dormancy.

Summary updated

Abstract

More than 70% of human breast cancers (BCs) are estrogen receptor α-positive (ER<sup>+</sup>). A clinical challenge of ER<sup>+</sup> BC is that they can recur decades after initial treatments. Mechanisms governing latent disease remain elusive due to lack of adequate in vivo models. We compare intraductal xenografts of ER<sup>+</sup> and triple-negative (TN) BC cells and demonstrate that disseminated TNBC cells proliferate similarly as TNBC cells at the primary site whereas disseminated ER<sup>+</sup> BC cells proliferate slower, they decrease CDH1 and increase ZEB1,2 expressions, and exhibit characteristics of epithelial-mesenchymal plasticity (EMP) and dormancy. Forced E-cadherin expression overcomes ER<sup>+</sup> BC dormancy. Cytokine signalings are enriched in more active versus inactive disseminated tumour cells, suggesting microenvironmental triggers for awakening. We conclude that intraductal xenografts model ER + BC dormancy and reveal that EMP is essential for the generation of a dormant cell state and that targeting exit from EMP has therapeutic potential.
BibTeX
@inproceedings{aouad2022epithelial,
  author = {Patrick Aouad and Yueyun Zhang and Fabio De Martino and Céline Stibolt and Simak Ali and Giovanna Ambrosini and Sendurai A. Mani and Kelly Maggs and Hazel M. Quinn and George Sflomos and Cathrin Brisken},
  title = {{Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence}},
  booktitle = {Nature Communications},
  year = {2022},
  doi = {10.1038/s41467-022-32523-6},
}
Figure